title: About the benefits of immunotherapy for high-risk neuroblastoma.
authors.forename: Lucas
authors.initials: L
authors.lastname: Moreno
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Barone
authors.forename: Julie R
authors.initials: JR
authors.lastname: Park
authors.forename: Andrew D J
authors.initials: AD
authors.lastname: Pearson
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D015474:Isotretinoin / Q000008:administration & dosage*; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015474:Isotretinoin